In vitro metabolic stabilities and metabolism of 2′-O-(Methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates

Oligonucleotides

Volumn 20, Issue 6, 2010, Pages 309-316

  Baek, Min Son ^a   Yu, Rosie Z ^a   Gaus, Hans ^a   Grundy, John S ^a   Geary, Richard S ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHOXYETHYL PHOSPHOROTHIOIC ACID; ANTISENSE OLIGONUCLEOTIDE; ISIS 104838; MIPOMERSEN; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ARTICLE; DEVELOPMENTAL STABILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER HOMOGENATE; MALE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN BINDING; PROTEIN STABILITY; RAT;

ANIMALS; BASE SEQUENCE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIVER; MALE; OLIGONUCLEOTIDES, ANTISENSE; ORGANOTHIOPHOSPHORUS COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

RATTUS;

EID: 78650365942     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2010.0252     Document Type: Article

References (33)

1. BENNETT, C.F., BUTLER, M., COOK, P.D., GEARY, R.S., LEVIN, A.A., MEHTA, R., TENG, C.-L., DESHMUKH, H., TILLMAN, L., and HARDEE, G. (2000). Antisense oligonu-cleotide-based therapeutics, in: Gene Therapy (Templeton NS and Lasic DD eds), pp 305-332, Marcel Dekker, Inc, New York.
2. BENNETT, C.F., and SWAYZE E.E. (2010). RNA targeting therapeutic: molecular mechanisms of antisense oligonucleotides as a therapeutic plat form. Annu. Rev. Pharmacol. Toxicol. 50, 259-293.
3. BRADLEY, J.D., CROOKE, R., KJEMS, L.L., GRAHAM, M., LEONG, R., YU, R., PAUL, D., and WEDEL, M. (2005). Hy-polipidemic effects of a novel inhibitor of human APO-B 100 in humans. Diabetes 54 (Suppl 1), 977.
4. CATTERALL, J.F., and WELKER, N.E. (1980). Purification and Properties of the Bst 1503 Endonuclease in Methods in En-zymology, vol. 65. (Academic Press Inc., Maryland Heights), pp. 167-170.
5. 0 methoxyethyl antisense to clustering, in patients with localized prostate cancer. J. Natl. Cancer Inst. 97, 1287-1296.
6. COOK, P.D. (1998). Antisense medicinal chemistry. In: Anti-sense Research and Application. S.T. Crooke ed. (Springer-Verlag, Berlin), pp. 51-101.
7. CROOKE, R.M., GRAHAM, M.J., LEMONIDIS, K.M., WHIPPLE, C.P., KOO, S., and PERERA, R.J. (2005). An apolipoprotien B antisense oligonucleotide lowers LDL cholesterol in hyperlipi-demic mice without acusing hepatic steatosis. J. Lipid Res. 46, 872-884.
8. CROOKE, R.M., MARTIN, M.J., LEMOMIDIS, K.M., WYRZ-KEIVEICZ, T., and CUMMINS, L.L. (2000). Metabolism of an-tisense oligonucleotides in rat liver homogenates. J. Pharmacol. Exp. Ther. 292, 140-149.
9. DESCHENES, J., VALET, J.P., and MARECEAU, N. (1980). Hepatocytes from newborn and weanling rats in monolayer culture: Isolation by perfusion, fibronectin-mediated adhesion, spreading and functional activities. In Vitro 16, 722-730.
10. EUN, H.M. (1996). Nucleases. In Enzymology Primer for Recombinant DNA Technology. (Academic Press Inc., Maryland Heights), pp. 145-232.
11. GARLICK, P.J., WATERLOW, J.C., and SWICK, R.W. (1976). Measurement of protein turnover in rat liver. Biochem. J. 156, 657-663.
12. GAUS, H.J., OWENS, S.R., WINNIMAN, M., COOPER, S., and CUMMINS, L.L. (1997). On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal. Chem. 36, 313-319.
13. GEARY, R.S., MATSON, J., and LEVIN, A.A. (1999). A non-radioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue. Anal. Biochem. 274, 241-248.
14. 0-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296, 898-904.
15. 0-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890-897.
16. GEARY, R.S., YU, R.Z., and LEVIN, A.A. (2001c). Pharmacoki-netics of phosphorothioate antisense oligonucleotides. Curr. Opin. Invest. Drugs 2, 562-573.
17. 0-O-(2-methoxyethyl) modified antisense oligonucleotide, comparison across species. Drug Metab. Dispos. 31, 1419-1428.
18. GRAHAM, M.J., CROOKE, S.T., MONTEITH, D.K., COOPER, S.R., LEMONIDIS, K.M., STECKER, K.K., MARTIN, M.J., and CROOKE, R.M. (1998). In vivo distribution and metabolism of a phosphothioate oligonucleotide within rat liver after intravenous administration. J. Pharmacol. Exp. Ther 286, 447-458.
19. HENRY, S.P., GEARY, R.S., YU, R.Z., and LEVIN, A.A. (2001). Drug proterties of second-generation antisense oligonucleo-tides, How do they measure up to their predecessors? Curr. Opin. Invest. Drugs 2, 1444-1449.
20. JONES, B.A., and SCHREIBER, A.D. (2005). mRNA as a therapeutic tatget in lung disease. Drug Des. Rev. 2, 361-372.
21. KASTELEIN, J.J.P., WEDEL, M.K., BAKER, B.F., SU, J., BRADLEY, J.D., YU, R.Z., CHUANG, E., GRAHAM, M.J., and CROOKE, R.M. (2006). Potent reduction of apolipoprotein B and LDL cholesterol by an antisense inhibitor of apolipopro-tein B. Circulation 114, 1729-1735.
22. KJEMS, L. (2005). New targets for glycemic control protein-tyrosine- phosphatase-1B antisense inhibitor. 65th Annual Meeting of the American Diabetes Association; 2005 June 10-14; San Diego CA. American Diabetes Association, Alexandria, VA.
23. LEVIN, A.A., YU, R.Z., and GEARY, R.S. Basic principles of the pharmacokinetics of antisense oligonucleotides drugs. In: Antisense Drug Technology. Stanley T. Crooke, ed (CRC Press, Boca Raton, FL), pp 183-215.
24. LU, C., LI, P., GALLEGOS, R., UTTAMSINGH V., XIA, C.Q., MIWA, G.T., BALANI, S.K., and GAN, L.S. (2006). Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab. Dispos. 34, 1600-1605.
25. PHILIPS, J.A., CRAIG, S.J., BAYLEY, D., CHRISTIAN, R.A., GEARY, R.S., and NICKLIN, P.L. (1997). Pharmacokinetics, metabolism, and elimination of a 20-mer phosphrothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharm. 54, 657-668.
26. 0-methoxyethyl modified anti-sense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol. Exp. Ther. 303, 1334-1343.
27. SWAYZE, E.E., and BHAT, B. (2008). The medicinal chemistry of oligonucleotides. In: Antisense Drug Technology. Stanley T. Crooke, ed. (CRC Press, Boca Raton, FL), pp. 147-153.
28. 0-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol. 6, 535-539.
29. WATANABE, T.A., GEARY, R.S., and LEVIN, A.A. (2006). Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 16, 169-180.
30. WEI, N., FIECHTNER, J., BOYLE, D., KAVANAUGH, A., DELAUTER, S., ROSENGREN, S., FIRESTEIN, G.S., TAMI, J., YU, R., and SEWELL, L. (2003). Synovial biomarker study of ISIS 104838, an antisense oligodeoxynucleotide targeting TNF-a, in rheumatoid arthritis. 67th Annual meeting of the American College of Rheumatology; 2003 October 23-28; Orlando, FL. American College of Rheumatology, Atlanta, GA.
31. 0-O-(2-methoxy) ethyl modified antisense oli-gonucleotides in monkeys. J. Pharm. Sci. 93, 48-59.
32. YU, R.Z., KIM, T.W., HONG, A., WATANABE, T.A., GAUS, H.J., and GEARY, R.S. (2007). Cross-species pharmacokinetic comparison from mouse to man of a second-generation anti-sense oligonucleotide, ISIS 301012, targeting human apolipo-protein B-100. Drug Metab. Dispos. 35, 460-468.
33. YU, R.Z., LEMONIDIS, K.M., GRAHAM, M.J., MATSON, J.E., CROOKE, R.M., TRIBBLE, D.L., WEDEL, M.K., LEVIN, A.A., and GEARY, R.S. (2009). Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol. 77, 910-919.